Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer

详细信息    查看全文

• 作者：Rabih Said ; Yang Ye ; David S. Hong ; Aung Naing…
• 关键词：Lenalidomide ; FOLFOX ; Phase I trial ; Advanced cancer
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：77
• 期：3
• 页码：575-581
• 全文大小：586 KB
• 参考文献：1. http://​www.​fda.​gov/​downloads/​drugs/​drugsafety/​ucm111335.​pdf.​ (2014)
  2.Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625–1630CrossRef PubMed
  3.Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386PubMed
  4.Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG (2002) Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130(1):75–84PubMedCentral CrossRef PubMed
  5.Sharpe AH, Abbas AK (2006) T-cell costimulation–biology, therapeutic potential, and challenges. N Engl J Med 355(10):973–975. doi:10.​1056/​NEJMp068087 CrossRef PubMed
  6.LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103(5):1787–1790. doi:10.​1182/​blood-2003-02-0361 CrossRef PubMed
  7.Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB (2011) Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother CII 60(1):61–73. doi:10.​1007/​s00262-010-0919-9 CrossRef PubMed
  8.Teo SK (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7(1):E14–E19. doi:10.​1208/​aapsj070103 PubMedCentral CrossRef PubMed
  9.Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1–2):56–63. doi:10.​1016/​j.​mvr.​2005.​01.​002 CrossRef PubMed
  10.Kim K, An S, Cha HJ, Choi YM, Choi SJ, An IS, Lee HG, Min YH, Lee SJ, Bae S (2013) Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett 5(2):588–592. doi:10.​3892/​ol.​2012.​1054 PubMedCentral PubMed
  11.Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M (2011) Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 35(3):380–386. doi:10.​1016/​j.​leukres.​2010.​09.​027 CrossRef PubMed
  12.Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77(2):78–86. doi:10.​1016/​j.​mvr.​2008.​08.​003 CrossRef PubMed
  13.Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2012) Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate 72(8):856–867. doi:10.​1002/​pros.​21488 CrossRef PubMed
  14.Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2009) Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 101(5):803–812. doi:10.​1038/​sj.​bjc.​6605206 PubMedCentral CrossRef PubMed
  15.Segler A, Tsimberidou AM (2012) Lenalidomide in solid tumors. Cancer Chemother Pharmacol 69(6):1393–1406. doi:10.​1007/​s00280-012-1874-2 CrossRef PubMed
  16.Papadopoulos KMD, Preston G (2005) A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors. Clin Cancer Res Abstr Int Conf Mol Targets Cancer Ther 11:215
  17.Petrylak DP R-GK, Tibyan M, Mohile SG (2009) A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 5156)
  18.Leuci V, Maione F, Todorovic M, Giraudo E, Gammaitoni L, Migliardi G, Aglietta M, Leone F, Trusolino L, Bertotti A, Sangiolo D (2013) Preclinical activity of lenalidomide in metastatic colorectal cancer. J Clin Oncol 31, 2013 (suppl; abstr e14654)
  19.Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87(10):1166–1172. doi:10.​1038/​sj.​bjc.​6600607 PubMedCentral CrossRef PubMed
  20.Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM (2013) Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest N Drugs 31(6):1505–1513. doi:10.​1007/​s10637-013-0013-1 CrossRef
  21.Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM (2014) Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest N Drugs 32(2):279–286. doi:10.​1007/​s10637-013-9966-3 CrossRef
  22.Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R (2012) Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18(22):6373–6383. doi:10.​1158/​1078-0432.​CCR-12-1627 PubMedCentral CrossRef PubMed
  23.Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D (2014) Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 20(18):4827–4836. doi:10.​1158/​1078-0432.​CCR-14-0603 PubMedCentral CrossRef PubMed
  24.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRef PubMed
  25.Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J (2010) Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 116(1):146–154. doi:10.​1002/​cncr.​24686 PubMed
  26.Glaspy J, Atkins MB, Richards JM, Agarwala SS, O’Day S, Knight RD, Jungnelius JU, Bedikian AY (2009) Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 115(22):5228–5236. doi:10.​1002/​cncr.​24576 CrossRef PubMed
  27.Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107(11):2609–2616. doi:10.​1002/​cncr.​22290 CrossRef PubMed
  28.Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer I (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351. doi:10.​1056/​NEJMoa032709 CrossRef PubMed
  29.Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology G (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431–436. doi:10.​1200/​JCO.​2005.​03.​0221 CrossRef PubMed
  30.Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working G (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423. doi:10.​1038/​sj.​leu.​2405062 CrossRef PubMed
  
• 作者单位：Rabih Said (1) (2)
  Yang Ye (1)
  David S. Hong (1)
  Aung Naing (1)
  Gerald Falchook (3)
  Siqing Fu (1)
  Jennifer J. Wheler (1)
  Sarina Piha-Paul (1)
  Apostolia-Maria Tsimberidou (1)
  
  1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
  2. Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX, USA
  3. Sarah Cannon Research Institute, Denver, CO, USA
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Purpose Lenalidomide has synergistic anticancer effects when used with chemotherapy. We conducted a phase I study of lenalidomide in combination with FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) in patients with advanced cancer.